Akari Therapeutics, Plc (AKTX) /
The cash flow of Akari Therapeutics, Plc over the past 10 years
Chart Akari Therapeutics, Plc: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2019, Akari Therapeutics, Plc's operating cash flow was -$12.92M and its capital expenditures $0, leaving free cash flow of -$12.92M. Free cash flow was below zero in all 4 years shown. It ranged from -$31.64M in fiscal 2017 to -$12.92M in fiscal 2019. Capital expenditures were highest in fiscal 2016, at $54.75K. No free cash flow figure is on file for fiscal 2020, 2021, 2022, 2023, 2024 and 2025.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$10.57M | — | — |
| 2024ended Dec 31, 2024 | -$12.55M | — | — |
| 2023ended Dec 31, 2023 | -$16.43M | — | — |
| 2022ended Dec 31, 2022 | -$21.5M | — | — |
| 2021ended Dec 31, 2021 | -$18.85M | — | — |
| 2020ended Dec 31, 2020 | -$16.95M | — | — |
| 2019ended Dec 31, 2019 | -$12.92M | $0 | -$12.92M |
| 2018ended Dec 31, 2018 | -$22.77M | $0 | -$22.77M |
| 2017ended Dec 31, 2017 | -$31.6M | $36.88K | -$31.64M |
| 2016ended Dec 31, 2016 | -$24.62M | $54.75K | -$24.68M |
Fiscal years as Akari Therapeutics, Plc reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Akari Therapeutics, Plc
- The profitability of Akari Therapeutics, Plc
- The debt of Akari Therapeutics, Plc
- All of Akari Therapeutics, Plc's financials, charted
Companies of a similar size
- TSLATesla, Inc.
- LLYELI LILLY AND COMPANY
- AVGOBroadcom Inc.
- MUMicron Technology, Inc.
- METAMeta Platforms, Inc.
Not investment advice. This page shows what Akari Therapeutics, Plc filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.